C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors Makes New $478,000 Investment in Exact Sciences Co. (NASDAQ:EXAS)

C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors bought a new stake in Exact Sciences Co. (NASDAQ:EXAS) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 8,508 shares of the medical research company’s stock, valued at approximately $478,000.

A number of other hedge funds also recently bought and sold shares of EXAS. Groupama Asset Managment purchased a new position in shares of Exact Sciences during the 3rd quarter worth $821,000. ArrowMark Colorado Holdings LLC purchased a new position in shares of Exact Sciences in the third quarter valued at approximately $28,608,000. Iron Triangle Partners LP acquired a new position in shares of Exact Sciences in the third quarter worth $27,239,000. Erste Asset Management GmbH acquired a new position in Exact Sciences during the 3rd quarter worth $26,546,000. Finally, Bellevue Group AG grew its position in shares of Exact Sciences by 25.1% during the third quarter. Bellevue Group AG now owns 1,449,465 shares of the medical research company’s stock worth $98,738,000 after buying an additional 290,585 shares in the last quarter. Institutional investors and hedge funds own 88.82% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently commented on EXAS. Evercore ISI dropped their target price on Exact Sciences from $80.00 to $60.00 and set an “outperform” rating on the stock in a report on Wednesday, November 6th. Benchmark reiterated a “buy” rating and issued a $65.00 price target on shares of Exact Sciences in a research report on Monday, January 13th. BTIG Research increased their price objective on Exact Sciences from $65.00 to $75.00 and gave the stock a “buy” rating in a research report on Tuesday, November 26th. Stifel Nicolaus lowered their target price on shares of Exact Sciences from $82.00 to $67.00 and set a “buy” rating on the stock in a report on Wednesday, November 6th. Finally, The Goldman Sachs Group dropped their price objective on Exact Sciences from $75.00 to $65.00 and set a “buy” rating on the stock in a report on Wednesday, November 6th. One investment analyst has rated the stock with a hold rating and eighteen have assigned a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $72.76.

Exact Sciences Trading Up 1.7 %

Shares of EXAS stock opened at $50.48 on Thursday. The company has a current ratio of 2.12, a quick ratio of 1.93 and a debt-to-equity ratio of 0.72. The company has a market capitalization of $9.34 billion, a price-to-earnings ratio of -43.14 and a beta of 1.24. The firm has a 50-day moving average price of $55.41 and a 200 day moving average price of $60.10. Exact Sciences Co. has a twelve month low of $40.62 and a twelve month high of $79.62.

Exact Sciences (NASDAQ:EXAS) last released its earnings results on Wednesday, February 19th. The medical research company reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.29) by $0.23. Exact Sciences had a negative return on equity of 6.17% and a negative net margin of 7.95%. Research analysts forecast that Exact Sciences Co. will post -1.1 earnings per share for the current fiscal year.

About Exact Sciences

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.